Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GL1DER HIV RCT
NCT07221214Phase 2Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2026
- Primary completion
- Oct 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in alcohol use disorder (AUD), Tobacco Use Disorder (TUD), cardiovascular disease (CVD), sponsored by Vanderbilt University Medical Center. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
alcohol use disorder (AUD)Tobacco Use Disorder (TUD)cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT07221214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221214.